Novocol Healthcare, Inc. (NHI), a subsidiary of Septodont, Inc., a world leader in sterile injectable manufacturing, announced today the acquisition of a majority stake in Duoject Medical Systems, Inc. (Duoject), a supplier of innovative medical devices. The synergy between the companies will bring additional value to NHI development projects, and will allow NHI to offer a broad array of injection devices and reconstitution systems to its pharmaceutical filling customers. Todd Beechey, President of NHI, commented, “The acquisition of Duoject enables NHI to offer a more complete and differentiated line of drug filling and delivery solutions to our customers. The acquisition of Duoject transforms NHI’s injectable business from a sterile injectable filling company to a one-stop source for device design and development, and pharmaceutical filling and supply of unique injectable products.”
NHI is focused on partnering with pharmaceutical and device companies to utilize its specialized manufacturing capabilities. NHI is collaborating with large multinational partners as well as niche companies to bring significant differentiation to their development projects and commercial products. Through its sister-company, Novocol Pharmaceutical of Canada, Inc., NHI offers manufacturing expertise including sterile filling of cartridges, and semi-solid dosage forms including creams, ointments, topical solutions and gels. For more information about NHI go to www.novocolhealthcare.com
Duoject is a supplier of innovative medical devices and design and development services, located in Québec Canada. With an internationally recognized expertise in design innovation, Duoject’s technologies provide customers with the ability to manage and extend their product life cycles and differentiate their own product offerings in competitive markets.
For more information about Duoject go to www.duoject.com.
